| __timestamp | Gilead Sciences, Inc. | Ligand Pharmaceuticals Incorporated |
|---|---|---|
| Wednesday, January 1, 2014 | 3788000000 | 9136000 |
| Thursday, January 1, 2015 | 4006000000 | 5807000 |
| Friday, January 1, 2016 | 4261000000 | 5571000 |
| Sunday, January 1, 2017 | 4371000000 | 5366000 |
| Monday, January 1, 2018 | 4853000000 | 6337000 |
| Tuesday, January 1, 2019 | 4675000000 | 11347000 |
| Wednesday, January 1, 2020 | 4572000000 | 30419000 |
| Friday, January 1, 2021 | 6601000000 | 62176000 |
| Saturday, January 1, 2022 | 5657000000 | 52827000 |
| Sunday, January 1, 2023 | 6498000000 | 35049000 |
| Monday, January 1, 2024 | 28675800000 |
Unleashing the power of data
In the competitive world of biotechnology, cost efficiency is a critical factor for success. Gilead Sciences, Inc. and Ligand Pharmaceuticals Incorporated, two prominent players in the industry, have shown contrasting trends in their cost of revenue from 2014 to 2023. Gilead Sciences, with its robust portfolio, has consistently maintained a high cost of revenue, peaking at approximately $6.6 billion in 2021. This represents a 74% increase from 2014, reflecting its expansive operations and market reach. In contrast, Ligand Pharmaceuticals, a smaller entity, has demonstrated a more volatile pattern, with its cost of revenue surging by over 580% from 2014 to 2021, reaching around $62 million. This stark difference highlights the diverse strategies and market positions of these companies. As the biotech landscape evolves, understanding these financial dynamics offers valuable insights into their operational efficiencies and strategic priorities.
Cost of Revenue Comparison: AbbVie Inc. vs Gilead Sciences, Inc.
Comparing Cost of Revenue Efficiency: Amgen Inc. vs Gilead Sciences, Inc.
Comparing Cost of Revenue Efficiency: Sanofi vs Ligand Pharmaceuticals Incorporated
Cost of Revenue: Key Insights for Gilead Sciences, Inc. and Intra-Cellular Therapies, Inc.
Comparing Cost of Revenue Efficiency: Gilead Sciences, Inc. vs Alkermes plc
Cost Insights: Breaking Down Gilead Sciences, Inc. and Wave Life Sciences Ltd.'s Expenses
Cost of Revenue: Key Insights for Gilead Sciences, Inc. and Iovance Biotherapeutics, Inc.
Comparing Cost of Revenue Efficiency: Gilead Sciences, Inc. vs Travere Therapeutics, Inc.
Analyzing Cost of Revenue: Teva Pharmaceutical Industries Limited and Ligand Pharmaceuticals Incorporated
Analyzing Cost of Revenue: Incyte Corporation and Ligand Pharmaceuticals Incorporated
Comparing Cost of Revenue Efficiency: Perrigo Company plc vs Ligand Pharmaceuticals Incorporated
Cost of Revenue Comparison: Ligand Pharmaceuticals Incorporated vs Galapagos NV